n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide has been researched along with Osteosarcoma in 1 studies
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, S | 1 |
| Kubota, M | 1 |
| Lin, YW | 1 |
| Okuda, A | 1 |
| Matsubara, K | 1 |
| Wakazono, Y | 1 |
| Hirota, H | 1 |
| Kuwakado, K | 1 |
| Akiyama, Y | 1 |
1 trial available for n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide and Osteosarcoma
| Article | Year |
|---|---|
In vivo administration of granulocyte colony-stimulating factor promotes neutrophil survival in vitro.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Burkitt Lymphoma; Cell Survival; Child; C | 1994 |